Sarepta Therapeutics, Inc.
Morgan Stanley sees Clean beat with no red flags; expect SRPT up 5-10%
With a new CEO in place, the firm would expect lingering concerns from prior CEO Kaye's stepping aside to be assuaged
The firm views Ingram as an established industry player
Credit Suisse’s new 2017 estimate is $103M which is higher than its previous estimate of $89M
Despite continued worry around the launch, docs estimate that prescribing has almost doubled since the firm’s last survey